Clinical Trial

A Phase II Study of 9MW3811 in Patients With Pathological Scar

Name: A Phase II Study of 9MW3811 in Patients With Pathological Scar — clinical trial record (NCT07576608)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of 9MW3811 in patients with pathological scar.

Trial Details

NCT Number	NCT07576608
Lead Sponsor	Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions	Scar
Enrollment	30 participants
Start Date	2025-12-29
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-08